1: Chem Biodivers. 2007 Aug;4(8):1707-28. Medicinal chemistry endeavors around the phytocannabinoids. Stern E, Lambert DM. Drug Design and Discovery Center and Unité de Chimie pharmaceutique et de Radiopharmacie, Ecole de Pharmacie, Faculté de Médecine, Université catholique de Louvain, Avenue E. Mounier 73, U.C.L. 73.40, B-1200 Bruxelles. Over the past 50 years, a considerable research in medicinal chemistry has been carried out around the natural constituents of Cannabis sativa L. Following the identification of Delta9-tetrahydrocannabinol (Delta9-THC) in 1964, critical chemical modifications, e.g., variation of the side chain at C3 and the opening of the tricyclic scaffold, have led to the characterization of potent and cannabinoid receptor subtype-selective ligands. Those ligands that demonstrate high affinity for the cannabinoid receptors and good biological efficacy are still used as powerful pharmacological tools. This review summarizes past as well as recent developments in the structure-activity relationships of phytocannabinoids. PMID: 17712816 [PubMed - indexed for MEDLINE] Related Links Recent developments in cannabinoid ligands. [Life Sci. 2005] PMID:15993427 Structure-activity relationships defining the ACD-tricyclic cannabinoids: cannabinoid receptor binding and analgesic activity. [Drug Des Discov. 1995] PMID:8872458 Homology model of the CB1 cannabinoid receptor: sites critical for nonclassical cannabinoid agonist interaction. [Biopolymers. 2003] PMID:12767117 The search for selective ligands for the CB2 receptor. [Curr Pharm Des. 2000] PMID:10903395 Behavioral effects of cannabinoid agents in animals. [Crit Rev Neurobiol. 1999] PMID:10803637